Linfoma de Burkitt do cólon direito num jovem adulto
DOI:
https://doi.org/10.24950/rspmi.1017Palavras-chave:
Linfoma de Burkitt, gene c-myc, vírus Epstein-Barr, regime Hiper-CVADResumo
O linfoma de Burkitt é um linfoma não Hodgkin de células B de
alto grau, pouco comum em adultos, e que compreende três variantes: a endémica, a esporádica e um subgrupo de linfomas
agressivos que ocorre em indivíduos imunodeprimidos.
É o primeiro tumor que se confirmou estar associado a um vírus
(Epstein-Barr) e a translocações cromossómicas, cuja consequência é bem conhecida - desregulação do oncogene c-myc.
Descreve-se o caso de um doente do sexo masculino com 23
anos de idade, raça negra, natural e residente em São Tomé e
Príncipe, com queixas de dor abdominal difusa, massa no flanco
direito, com aumento do volume abdominal e períodos que alternavam entre diarreia e obstipação.
Após a realização de exames complementares foi-lhe diagnosticado linfoma de Burkitt em estádio III, tendo iniciado protocolo
Hiper-CVAD de oito ciclos.
Downloads
Referências
Leval L. and. Hasserjian R. P, “Diffuse large B-cell lymphomas and burkitt lymphoma,” Hematology/Oncology Clinics of North America 2009; 23(4): 791–827.
God J., Haque A., Burkitt Lymphoma: Pathogenesis and Immune Evasion,Journal of Oncology 2010; 2010: 516047.
Magrath I., Venkatesh H, Gascoyne R. Chapter 30 Burkitt’s Lymphoma. In Mauch Peter M.ed. Non-Hodgkin’s Lymphomas. Lippincott Williams & Wilkins; 1 edition 2003: 496-477.
Chehab, B., Schultz T., Nassif I., Adult Burkitt-like lymphoma of the colon: acase report and a review of the literature; Gastrointestinal endoscopy journal 2008; 67(7):1204-1206.
Kristie A. Blum, Gerard Lozanski, and John C. Byrd; Adult Burkitt leukemia and lymphoma; The American Society of Hematology 2004; 104(10): 3009-3020.
Ferry J., Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis; The Oncologist, 2006; 11(4): 375-383.
Boerma, EG, van Imhoff, GW, Appel, IM, et al. Gender and age-related differences in Burkitt lymphoma-epidemiological and clinical data from The Netherlands. Eur J Cancer 2004; 40(18): 2781-2787.
Wayne A., Wilson W. Burkitt’s and Lymphoblastic Lymphomas. In Sweetencham J, Williams M. eds. Lymphoma, pathology, diagnostic and treatment; Cambridge Medicine 2007: 182-199
Armitage, JO, Weisenburger, DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16(8): 2780-2795.
Martin J. Allday; How does Epstein–Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt’s lymphoma?; Seminars in Cancer Biology 2009; 19(6); 366-376.
Burkitt, D. A children’s cancer dependent on climatic factors. Nature 1962;194:232-234.
Aster J. Doenças de leucócitos, gânglios, baço e timo. In Abbas A.,Fausto N. eds. Robbins e Cotran - Bases Patológicas das Doenças.
Elsevier 2004: 695-745.
Wong M, Eu K. Primary colorectal lymphomas. Colorectal Dis 2006;8:586-591.
Carvalho L.,Mallmann A.,e tal. Linfoma do cego, relato de caso, Brasil Coloproct 2000; 20:172-174.
Glick, DD, Soule, EH. Primary malignant lymphoma of colon or appendix. Report of 27 cases. Arch Surg 1966;92:144-151.
Perry, PM, Cross, RM, Morson, BC. Primary malignant lymphoma of the rectum (22 cases). Proc R Soc Med 1972; 65:72..
Bellan, C, Lazzi, S, Hummel, M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005; 106(3): 1031-1036.
Hecht J, Aster J. Molecular biology of Burkitt’s lymphoma. J Clin Oncol.2000; 18(21):3707-3721.
Gerbitz A, Mautner J, Geltinger C, et al. Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt’s lymphoma. Oncogene.1999; 18(9):1745-1753.
Photo image source Gregory Schuler, NCBI,NLM,NIH: http://www.ncbi.nlm.nih.gov/books/NBK22257
Queiroga,E; Gualco G et al, Viral Studies in Burkitt Lymphoma: Association With Epstein-Barr Virus but Not HHV-8; American Journal of Clinical Pathology. 2008;130(2): 186-192.
Magluta E; Klumb C;Ttreatment resistance in Burkitt’s lymphoma: Is it associated with specific mutations of the TP53 gene?; Revista brasileira de Hematologia e Hemoterapia 2008; 30(1): 41-46.
Photo image by Dr. Louis Staudt; Gene Expression Profiling Distinguishes Lymphomas; NIH:http://www.nih.gov/researchmatters/june2006/06092006lymphoma.htm
Photo image source The Stanford Cytopathology Service; Stanford School of Medicine: http://cytopathology.stanford.edu/
Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardimiman JW. WHO classification of tumours. Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001: 181-184.
Broyde A., Boycov O., Strenov Y., Okon E., Shpilberg O., Bairey O.; Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma; American Journal of Hematology 2009;84(6): 338-343.
Fermé C,Vanel D., Ribrag V, Girinski T; Role of imaging to choose treatment; Cancer Imaging 2005: 5 Spec No A:S113-119.
Murphy SB. Childhood non-Hodgkin lymphom. N Engl J Med 1978; 299:1446–1448.
Foon,K., Ghobrial,I., Geskin,L. et al. The Non-Hodgkin Lymphomas. In Lichtman, M., Beutler, E., Kipps,T. et al(eds.).Williams Hematology- 7th edition. New York, New York: The McGraw-Hill Companies 2006: 1407-1461.
www.uptodate.com
Bishop, PC, Rao, VK, Wilson, WH. Burkitt’s lymphoma: molecular pathogenesis and treatment. Cancer Invest 2000; 18(6):574-583.
Kantarjian, HM, O’Brien, S, Smith, TL, et al. Results of treatment with hyperCVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547.
Thomas, DA, Cortes, J, O’Brien, S, et al. Hyper-CVAD program in Burkitt’stype adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17:2461.
Hoelzer, D, Ludwig, WD, Thiel, E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87:495.
Nademanee, A, Molina, A, O’Donnell, MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997; 90:3844.
Song, KW, Barnett, MJ, Gascoyne, RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 2006; 133(6):634-637.
Van Imhoff, GW, van der Holt, B, MacKenzie, MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19:945.
Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphomawith dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome (abstract). Blood 2006;108:774ª.
Cheson, BD, Pfistner, B, Juweid, ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
